| Dr Timothy D Robison, MD | |
|
200 S 37th St, Muskogee, OK 74401-4928 | |
| (918) 683-8100 | |
| (918) 683-8198 |
| Full Name | Dr Timothy D Robison |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 43 Years |
| Location | 200 S 37th St, Muskogee, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780638155 | NPI | - | NPPES |
| 100110660B | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 13838 (Oklahoma) | Secondary |
| 174400000X | Specialist | 13838 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Francis Hospital Muskogee | Muskogee, OK | Hospital |
| Entity Name | Muskogee Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316072747 PECOS PAC ID: 0749245256 Enrollment ID: O20041124000017 |
News Archive
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
A series of studies presented Monday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles suggest that the benefits of breast-feeding in developing countries might outweigh the risk of vertical HIV transmission, the San Francisco Chronicle reports.
IMS Health today announced that John R. Walsh has been named senior vice president, Payer and Government Solutions, a new position. Previously, Walsh was senior vice president, Strategy and Business Development for IMS. He continues to report to David R. Carlucci, IMS chairman and CEO, and will be based in Norwalk, CT.
BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.
In a guest post in the Center for Global Health Policy's "Science Speaks" blog, part of the blog's coverage leading up to World Tuberculosis Day, Madhukar Pai, an associate professor of epidemiology at McGill University, Montreal, and an associate director of the McGill International TB Centre, "looks at the need for an evolving approach to tuberculosis."
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy D Robison, MD 200 S 37th St, Muskogee, OK 74401-4928 Ph: (918) 683-8100 | Dr Timothy D Robison, MD 200 S 37th St, Muskogee, OK 74401-4928 Ph: (918) 683-8100 |
News Archive
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
A series of studies presented Monday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles suggest that the benefits of breast-feeding in developing countries might outweigh the risk of vertical HIV transmission, the San Francisco Chronicle reports.
IMS Health today announced that John R. Walsh has been named senior vice president, Payer and Government Solutions, a new position. Previously, Walsh was senior vice president, Strategy and Business Development for IMS. He continues to report to David R. Carlucci, IMS chairman and CEO, and will be based in Norwalk, CT.
BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.
In a guest post in the Center for Global Health Policy's "Science Speaks" blog, part of the blog's coverage leading up to World Tuberculosis Day, Madhukar Pai, an associate professor of epidemiology at McGill University, Montreal, and an associate director of the McGill International TB Centre, "looks at the need for an evolving approach to tuberculosis."
› Verified 3 days ago